Merck (MRK) Declares $0.45 Quarterly Dividend; 3.1% Yield
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Stocks fall as higher oil prices, Treasury yields weigh
Merck (MRK) Announces Positive CHMP Opinion for Pembrolizumab
May 22, 2015 7:25 AM EDTMSD, known as Merck (NYSE: MRK) in the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of pembrolizumab, the companys anti-PD-1 therapy, for the treatment of advanced (unresectable or metastatic) melanoma as both first-line therapy and in previously-treated patients. The CHMP positive opinion for pembrolizumab, which is based on data in more than 1,500 adult patients with advanced melanoma, will now be reviewed by the European Commission for central marketing authorization in the... More
Merck (MRK) Receives Positive EMA CHMP Opinion on KEYTRUDA as Advanced Melanoma Treatment
May 22, 2015 7:13 AM EDTMerck (NYSE: MRK) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, for the treatment of advanced (unresectable or metastatic) melanoma, as both first-line therapy and in previously treated patients. The CHMP positive opinion for KEYTRUDA, which is based on data in more than 1,500 adult patients with advanced melanoma, will now be reviewed by the European Commission for central marketing authorization in the European Union (EU).
Merck is committed to bringing... More
